Syn­log­ic, Gink­go ex­pand mi­cro­bial dis­cov­ery pact, throw­ing $80M in­vest­ment in­to the mix

For Gink­go Bioworks, team­ing up with Syn­log­ic on a pi­lot dis­cov­ery project late 2017 marked its for­ay in­to har­ness­ing the ther­a­peu­tic abil­i­ty of its cell pro­gram­ming plat­form. Hav­ing since leaped in­to a new an­tibi­otics ef­fort with Roche, Gink­go is anti­ng up $80 mil­lion to go deep­er with Syn­log­ic.

The two com­pa­nies, both based in the Cam­bridge/Boston hub, are un­veil­ing a new col­lab­o­ra­tion in which Gink­go will help op­ti­mize the mi­cro­bial strains that Syn­log­ic — a pi­o­neer in reengi­neer­ing non-path­o­gen­ic bac­te­ria in­to med­i­cines — has iden­ti­fied as vi­able drug can­di­dates.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN